House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Nephrology · Rheumatology

Lupus nephritis

KDIGO · 2024 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

KDIGO bases lupus-nephritis treatment on kidney biopsy class, activity versus chronic damage, kidney function and the patient’s wider lupus manifestations. It adds belimumab and calcineurin-inhibitor combinations to established initial options while emphasizing sustained maintenance, adherence and toxicity prevention. A proteinuria result alone cannot define disease activity or justify escalation.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Detect kidney disease and establish its pattern

  • Check kidney function, urine sediment and proteinuria, anti-dsDNA and complement at lupus presentation and during surveillance. Kidney involvement can be silent; use repeated clinical and laboratory assessment rather than waiting for symptoms. [1]
  • Consider biopsy when the overall findings suggest nephritis. Proteinuria around 500 mg/day is a trigger for further investigation, not a safe exclusion threshold: severe active nephritis can have relatively little proteinuria. Biopsy distinguishes potentially reversible inflammation from chronic damage and guides classification and treatment. [1]

Provide kidney protection and reduce treatment harms

  • Treat lupus, including lupus nephritis, with hydroxychloroquine or an equivalent antimalarial unless contraindicated. This is a strong recommendation based on low-certainty evidence; dosing and toxicity surveillance still require the appropriate prescribing protocol. [1]
  • Address blood pressure, proteinuria and cardiovascular risk; avoid nephrotoxins and prevent acute kidney injury. Renoprotective medicines such as renin–angiotensin-system blockade or SGLT2 inhibitors are considered in stable patients without acute kidney injury, not automatically during an acute flare with kidney injury. [1]
  • Review infection risk and vaccination, bone health, contraception and fertility before and during immunosuppression. Assess hepatitis, HIV and tuberculosis risk and consider Pneumocystis prophylaxis with attention to adverse reactions. Prior cyclophosphamide exposure matters for fertility and malignancy risk. [1]

Match initial treatment to biopsy class and patient factors

  • Class I or II nephritis with low-level proteinuria generally needs no additional kidney-directed immunosuppression beyond treatment for extrarenal lupus. Nephrotic syndrome with these classes requires assessment for lupus podocytopathy, including electron microscopy where available; do not apply the low-proteinuria pathway unchanged. [1]
  • For active class III or IV nephritis, with or without a membranous component, start glucocorticoids plus one recommended regimen: a mycophenolic-acid analogue; low-dose IV cyclophosphamide; belimumab with either of those drugs; or mycophenolate plus a calcineurin inhibitor when kidney function is not severely impaired. [1]
  • A reduced glucocorticoid regimen after a short IV methylprednisolone pulse course may be considered when both kidney and extrarenal disease are improving satisfactorily. This is conditional on response, not an automatic steroid schedule for every presentation. [1]
  • For active class III/IV nephritis, IV cyclophosphamide can be useful when adherence to oral treatment is difficult. Prefer a mycophenolate-based initial regimen when infertility risk is high, including substantial previous cyclophosphamide exposure. [1]
  • A calcineurin-inhibitor-containing regimen may suit relatively preserved kidney function with nephrotic proteinuria from podocyte injury, or selected patients unable to tolerate standard mycophenolate or use cyclophosphamide. Belimumab-based triple treatment may suit repeated kidney flares or high risk of progression from severe chronic kidney disease. [1]
  • If standard initial drugs cannot be used because of intolerance, availability or cost, alternatives such as azathioprine or leflunomide with glucocorticoids may be considered, with potentially inferior efficacy or greater toxicity. Rituximab may be considered for persistent activity or inadequate response to standard therapy. [1]

Maintain response long enough and taper carefully

  • After initial treatment of class III/IV nephritis, use a mycophenolic-acid analogue for maintenance. Azathioprine is an alternative when mycophenolate is not tolerated or accessible, or pregnancy is being considered. [1]
  • Taper maintenance glucocorticoids to the lowest possible dose unless extrarenal disease requires them. Consider discontinuation after complete clinical renal response has persisted for at least 12 months; this does not mean stopping all maintenance immunosuppression. [1]
  • For proliferative nephritis, initial plus combination maintenance immunosuppression should usually span at least 36 months. A belimumab- or calcineurin-inhibitor-containing triple regimen can continue into maintenance. If neither mycophenolate nor azathioprine is usable, consider other specialist-selected maintenance options. [1]

Reassess inadequate response before changing treatment

  • Assess proteinuria together with stabilization or improvement of kidney function and extrarenal lupus. Trial response windows are not instructions to wait while a patient deteriorates. Continuously improving patients may take longer to reach complete response; persistent activity can remain despite apparently satisfactory clinical results. [1]
  • For an unsatisfactory response, first verify adherence and adequate drug exposure. Consider repeat biopsy when chronic damage or another diagnosis is suspected, then switch to another recommended regimen if active disease persists. Refractory cases may warrant rituximab or another biologic, an extended IV cyclophosphamide course, or a clinical trial. [1]
  • Treat relapse after partial or complete remission with the original successful initial regimen or another recommended regimen. If a presumed flare could instead represent chronic damage, repeat biopsy can help avoid inappropriate escalation of immunosuppression. [1]
  • For pure class V nephritis, proteinuria severity and its complications drive treatment. For nephrotic-range proteinuria, mycophenolate is a reasonable first immunosuppressive choice alongside supportive care, within a regimen generally combining glucocorticoids with another agent; non-nephrotic proteinuria above 1 g/day requires individualized decisions based on progression and treatment risks. This pathway differs from proliferative or mixed class III/IV disease. [1]

Account for pregnancy, children and other kidney syndromes

  • In lupus nephritis with thrombotic microangiopathy, identify and treat the underlying cause. The specialist algorithm separates thrombotic thrombocytopenic purpura, antiphospholipid-associated disease and complement-mediated disease; they do not share one universal treatment. [1]
  • Advise avoiding pregnancy during active nephritis, during potentially teratogenic treatment and for at least 6 months after nephritis becomes inactive. Continue hydroxychloroquine during pregnancy and start low-dose aspirin before 16 weeks to reduce pregnancy complications. [1]
  • Pregnancy-compatible immunosuppressive options include glucocorticoids, hydroxychloroquine, azathioprine, tacrolimus and cyclosporine. This list does not make mycophenolate, cyclophosphamide or every newer lupus drug pregnancy-compatible. [1]
  • For children, use similar immunosuppressive principles while adapting dose, growth, fertility and psychosocial considerations. For kidney failure, haemodialysis, peritoneal dialysis and transplantation are options, with transplantation preferred to long-term dialysis. [1]

Limitations and use

  • Graded recommendations and ungraded practice points have different evidence status. This summary does not reproduce full biopsy scoring, class V algorithms, response criteria, thrombotic-microangiopathy branches or immunosuppressive dosing and monitoring tables.
  • Calcineurin-inhibitor selection requires kidney-function assessment and nephrotoxicity monitoring. This summary does not supply a universal eGFR eligibility threshold or interchangeable dosing across voclosporin, tacrolimus and cyclosporine.
  • Pregnancy planning and medicine changes require coordinated kidney, rheumatology and obstetric care. The pregnancy-compatible list is not a complete individual contraindication or monitoring assessment.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Lupus nephritis

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
KDIGO
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Detect kidney disease and establish its pattern
  • Provide kidney protection and reduce treatment harms
  • Match initial treatment to biopsy class and patient factors
  • Maintain response long enough and taper carefully
  • Reassess inadequate response before changing treatment
  • Account for pregnancy, children and other kidney syndromes
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House